-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A7V9QVgkMDv79ukpstorZghzto9JZ16qIZILy0/QtIxgodBSkoThEtDWpnrsxwBl E23MM9D2GiZX3burKm0Qmg== 0000912057-00-054073.txt : 20001220 0000912057-00-054073.hdr.sgml : 20001220 ACCESSION NUMBER: 0000912057-00-054073 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20001219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMATRIX INC CENTRAL INDEX KEY: 0000747952 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133058261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: SEC FILE NUMBER: 000-19373 FILM NUMBER: 791662 BUSINESS ADDRESS: STREET 1: 65 RAILROAD AVE CITY: RIDGEFIELD STATE: NJ ZIP: 07657 BUSINESS PHONE: 2019459550 MAIL ADDRESS: STREET 1: 65 RAILROAD AVE STREET 2: 65 RAILROAD AVE CITY: RIDGEFIELD STATE: NJ ZIP: 07657 15-12G 1 a2033657z15-12g.txt FORM 15-12G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 Certification and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports Under Sections 13 and 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-19373 GENZYME BIOSURGERY CORPORATION (F/K/A BIOMATRIX, INC.) ------------------------------------------------------ (Exact name of registrant as specified in its charter) ONE KENDALL SQUARE CAMBRIDGE, MA 02138 (617) 252-7500 -------------- (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) COMMON STOCK, $0.0001 PAR VALUE ------------------------------- (Title of each class of securities covered by this Form) NONE ---- (Title of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports: Rule 12(g)-4(a)(1)(i) [X] Rule 12h-3(b)(1)(ii) [ ] Rule 12(g)-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ] Rule 12(g)-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(i) [ ] Rule 12(g)-4(a)(2)(ii) [ ] Rule 15d-6 [ ] Rule 12h-3(b)(1)(i) [X] Approximate number of holders of record as of the certification or notice date: 1 Pursuant to the requirements of the Securities Exchange Act of 1934, Biomatrix, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person. Date: DECEMBER 19, 2000 GENZYME BIOSURGERY CORPORATION By: /S/ EARL M. COLLIER, JR. -------------------------------- Name: Earl M. Collier, Jr. Title: President -----END PRIVACY-ENHANCED MESSAGE-----